Kyowa Kirin buys back Tivozanib non-oncology rights from AVEO Oncology
The agreement is an amendment to the terms of the 2006 tivozanib license agreement between Kyowa Kirin and AVEO which granted AVEO exclusive rights of tivozanib in all
Superluminal Medicines secured $120m in a Series A funding round to advance the development of its assets into clinical trials.
The late-stage trial assessed the efficacy and safety of Kisqali plus fulvestrant combination in postmenopausal women having hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or
Dasotraline’s pharmacokinetic profile, characterized by an extended half-life, supports its potential for sustained control of moderate-to-severe BED symptoms. The action date by the FDA under the Prescription Drug